Navigation Links
Gen-Probe Announces $150 Million Stock Repurchase Plan
Date:2/15/2011

SAN DIEGO, Feb. 15, 2011 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that its board of directors has authorized the repurchase of up to $150 million of the Company's common stock over the next year.  

"Based on our healthy balance sheet and strong anticipated cash flows, we believe we can increase long-term shareholder value and offset dilution from employee option programs by buying back stock, while at the same time retaining the strategic and operational flexibility to invest appropriately in our business," said Herm Rosenman, Gen-Probe's senior vice president - finance, and chief financial officer.

Repurchases may occur from time to time and at Gen-Probe's discretion, depending on market conditions and other factors.  Shares may be purchased on the open market or through private transactions, pursuant to Rule 10b5-1 trading plans or other available means.

In the fourth quarter of 2010, Gen-Probe had 48.5 million shares of common stock outstanding on a weighted average, diluted basis.  As of December 31, 2010, the Company had $489.7 million of cash, cash equivalents and marketable securities, and $240.0 million of short-term debt.  The Company pays interest on this debt at a rate 0.6% above the one-month London Interbank Offered Rate (LIBOR), which was recently below 0.3%.  Gen-Probe generated $169.6 million of cash from operating activities in 2010, while spending $30.7 million on property, plant and equipment, leading to free cash flow of $138.9 million.

About Gen-ProbeGen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking StatementsAny statements in this news release regarding our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  For example, statements concerning future share repurchases are forward-looking statements.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied.  Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that unforeseen circumstances may prohibit Gen-Probe from executing its share repurchase program in whole or in part, (ii) the risk that share repurchases will not be accretive to earnings, (iii) the risk that Gen-Probe will not have adequate cash to execute on its strategic or operational initiatives, or will require debt to do so, and (iv) the risk that Gen-Probe's share price will not appreciate above the prices at which Gen-Probe repurchases shares.  The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.Contact:Michael Watts

Vice president, investor relations and corporate communications

858-410-8673
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
3. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
4. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
5. Neogen Acquires Gen-Probes BioKits Food Safety Business
6. Gen-Probe to Webcast Two Upcoming Investor Presentations
7. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
8. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
9. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
10. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
11. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light leaks to your ... clip to clip with high quality 4K lens flare footage," said Christina Austin - ... flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel lens ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... 05, 2016 , ... Edward Buckingham MD , and ... of the newest Sciton laser in January 2017. The Halo is the first ... ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically ...
(Date:12/5/2016)... ... , ... For many years, Andrew G. Zubinas has accumulated over ... of the Lithuanian language and its poetry inspired him in writing “ ... explores all aspects of a living, breathing forest where nothing ever stays the same. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted from December 5, ... Central Awards. , Awards include the Information Security Executive® of the Year, ...
Breaking Medicine News(10 mins):